VF
MBRX icon

Virtu Financial’s Moleculin Biotech MBRX Stock Holding History

Virtu Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,371
Closed -$18K – 1830
2025
Q2 		$18K Buy
+2,371
New +$48.6K ﹤0.01% 1264
2023
Q2 		– Sell
-44
Closed -$16K – 1817
2023
Q1 		$16K Buy
44
+7
+19% +$3.07K ﹤0.01% 1286
2022
Q4 		$15K Buy
+37
New +$15.6K ﹤0.01% 1320
2022
Q1 		– Sell
-124
Closed -$87K – 1800
2021
Q4 		$87K Buy
+124
New +$110K 0.01% 1181
2021
Q3 		– Sell
-67
Closed -$93K – 1771
2021
Q2 		$93K Buy
+67
New +$91.4K 0.01% 1225
2019
Q1 		– Sell
-6
Closed -$13K – 1667
2018
Q4 		$13K Buy
+6
New +$17.2K ﹤0.01% 1418
2018
Q2 		– Sell
-6
Closed -$24K – 2294
2018
Q1 		$24K Hold
6
– – ﹤0.01% 1803
2017
Q4 		$26K Buy
+6
New +$26K ﹤0.01% 2185

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
WDG
Wealth Dimensions Group Cincinnati, Ohio $508M AUM 15.32% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial's MBRX Position: Q3 2025 in Review

Virtu Financial sold out of Moleculin Biotech (MBRX) in Q3 2025, closing a stake of 2,371 shares — an estimated $18K sold.

Virtu Financial first reported a position in MBRX in Q4 2017 and held it in 8 quarters. The position peaked at $93K in Q2 2021. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2025.

  • Virtu Financial reported no remaining Moleculin Biotech position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 2,371 Moleculin Biotech shares in Q3 2025, an estimated $18K.
  • Virtu Financial first reported a position in Moleculin Biotech in Q4 2017 and held it in 8 quarters.
  • Virtu Financial's Moleculin Biotech position peaked at $93K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.